| Identification | Back Directory | [Name]
ZSET-845 | [CAS]
324077-62-5 | [Synonyms]
ZSET-845
ZSET 845,ZSET845
Imidazo[1,2-a]pyridin-2(3H)-one, 3,3-bis(phenylmethyl)- | [Molecular Formula]
C21H18N2O | [MDL Number]
MFCD30593521 | [MOL File]
324077-62-5.mol | [Molecular Weight]
314.38 |
| Chemical Properties | Back Directory | [Boiling point ]
466.5±28.0 °C(Predicted) | [density ]
1.14±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
3.57±0.40(Predicted) |
| Hazard Information | Back Directory | [Uses]
ZSET-845 is a cognitive enhancer which enhances choline acetyltransferase activity in the hippocampus in the rat. | [in vivo]
Treatment with ZSET-845 at the dose of 0.01, 0.1 and 1 mg/kg significantly ameliorates impaired performance caused by scopolamine. Oral administration of ZSET-845 causes an increase in ChAT activity in the hippocampus. In the hippocampus, ZSET-845 (0.01, 0.1 or 1 mg/kg) significantly increases ChAT activity (112%, 113.8% or 108.7%, respectively) compared with matched vehicle-injected control rats[1]. Oral administration of ZSET845 at a dose of 1 or 10 mg/kg ameliorates learning impairment in passive avoidance task and enhanced ChAT activity in the basal forebrain, medial septum and hippocampus, and increases in the number of ChAT-immunoreactive cells in the medial septum in Ab-treated rats to the levels of vehicle-injected control rats[2]. | [References]
[1] Yamaguchi Y, et al. Ameliorative effects of azaindolizinone derivative ZSET845 on scopolamine-induced deficits in passive avoidance and radial-arm maze learning in the rat. Jpn J Pharmacol. 2001 Nov;87(3):240-4. DOI:10.1254/jjp.87.240
[2] Yamaguchi Y, et al. Antiamnesic effects of azaindolizinone derivative ZSET845 on impaired learning and decreased ChAT activity induced by amyloid-beta 25-35 in the rat. Brain Res. 2002 Aug 2;945(2):259-65. DOI:10.1016/s0006-8993(02)02816-0 |
|
|